Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Viemed Healthcare Inc VMD

Viemed Healthcare, Inc. through its subsidiaries, is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counselling to patients in their homes using cutting edge technologies. The Company’s products and services... see more

NDAQ:VMD - Post Discussion

Viemed Healthcare Inc > VMD trades 7 times its 2021 Adj. EBITDA
View:
Post by stockfy on Nov 02, 2021 4:39pm

VMD trades 7 times its 2021 Adj. EBITDA

VMD's Enterprise Value currently is about $200 million (in USD) including its net cash position of course.

Adj. EBITDA in 2021 are estimated at about $30 million (in USD).

Therefore, VMD currently trades less than 7 times its adj. EBITDA. 

So VMD is cheap both on relative and absolute valuation analysis while maintaining a pristine balance sheet.  
Comment by JackLambert on Nov 02, 2021 5:04pm
I would remind any sceptics about this company - As Bob Dylan said - you're right from your side and I'm right from mine.   There are plenty of things to get upset about.   Any Long must be tens of thousands in the hole.   But so much of this is the pandemic.   All the numbers continue to say durable attractive growth in a very promising market.   And a bit of ...more  
Comment by checkup on Nov 02, 2021 5:32pm
This post has been removed in accordance with Community Policy
Comment by besttobe on Nov 02, 2021 5:12pm
Stockfy wrote "So VMD is cheap both on relative and absolute valuation analysis while maintaining a pristine balance sheet.  " So why is it cheap? Why does no one want to buy it? Must be a reason. NO?
Comment by jomen1789 on Nov 02, 2021 6:07pm
Why aren't the insiders buying some shares with their phantom share dividend if they believe the price targets set by RBC and Lake Street? They don't. Even when the share price drops, they still get a LOT of money from the Phantom Share dividend. Talk about ethical. Why isn't RBC or Lake Street themselves gobbling up shares at these dismal prices? They sure don't do as they ...more  
Comment by JackLambert on Nov 02, 2021 6:57pm
It's striking there have been no insider buys.  I would imagine there is a tacit understanding by management that the optics of a buy would be very bad.  And why buy now?  Wait three months and see what's going on with Covid.  Things were moving in June - then came delta   That central band of the US over to Colorado is where the cases are still growing   ...more  
Comment by jomen1789 on Nov 04, 2021 9:11pm
Stockfy is a liar and his "Adj. EBITDA in 2021 are estimated at about $30 million (in USD)." is a number conjured out of his butt. The official news release from Viemed states that after 3 quarters, Adjusted Ebitda is $19.7 million. My number can be verified at this link, I'm not a liar like Stockfy https://stockhouse.com/news/press-releases/2021/11/01/viemed-healthcare-announces ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities